Takeda is said to be considering a bid for rare disease specialist Shire that could top $40 billion. Shire's shares were up as much as 26 % on the news.
It is considered that Takeda’s public statement that it is considering an approach for Shire will inevitably flush out other big pharma players including Pfizer, Novartis and AbbVie, leading to a competitive M&A situation.
As posted in January, Takeda has been active over the past year or so in seeking rare disease deals/collaborations to bolster its neuroscience division.
https://www.cnbc.com/2018/03/28/japans-takeda-is-considering-a-bid-for-british-drugmaker-shire.html
https://hotcopper.com.au/threads/2017-2018.3940742/page-82?post_id=30121049#.WrwYQIhuaUk
Takeda is said to be considering a bid for rare disease...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |